Skip to content
Marker Therapeutics, Inc.
Marker Therapeutics, Inc.
  • About
    • Overview
    • Company Management
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Multi Antigen Targeted T Cell Therapies
    • T Cell Vaccines
    • PolyStart™
  • Clinical Studies
    • Pipeline
    • MultiTAA T Cell Therapy
    • TPIV200
    • TPIV100/110
  • Investors
    • Overview
    • Briefcase
    • Stock Information
    • Financial Filings
    • Research Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Email Alerts
  • News & Media
    • Press Releases
    • Media Coverage
    • Event Calendar
    • Press Kit / Media
  • Careers
  • Contact
  • About
    • Overview
    • Company Management
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Multi Antigen Targeted T Cell Therapies
    • T Cell Vaccines
    • PolyStart™
  • Clinical Studies
    • Pipeline
    • MultiTAA T Cell Therapy
    • TPIV200
    • TPIV100/110
  • Investors
    • Overview
    • Briefcase
    • Stock Information
    • Financial Filings
    • Research Analyst Coverage
    • Corporate Governance
    • Shareholder FAQ
    • Email Alerts
  • News & Media
    • Press Releases
    • Media Coverage
    • Event Calendar
    • Press Kit / Media
  • Careers
  • Contact

Daily Archives: January 3, 2018

You are here:
  1. Home
  2. 2018
  3. January
  4. 03

TapImmune to Present at Biotech Showcase™ 2018

Featured, Press ReleasesBy Aaron SantosJanuary 3, 2018

TapImmune President & CEO, Peter Hoang, to present at Biotech Showcase next week.

SIGN UP FOR EMAIL ALERTS

Get Marker News Delivered To Your Inbox

Sign Up Today

Join the MRKR VIP List